ReviewMycoses2026
Hidden Mould in the Air: A Practical Narrative Mini-Review of Invasive Mould Infection Prevention for High-Risk Patients and Clinicians.
Review in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Airborne mould spores, including those of the Aspergillus species, are ubiquitous both indoors and outdoors. While they are generally harmless, inhaled spores can cause severe infections, particularly invasive pulmonary aspergillosis, in patients with impaired immune defences. Allergic manifestations such as asthma arise by different mechanisms and are not covered. This narrative mini-review summarises key evidence and guideline recommendations for healthcare teams and provides practical, patient-friendly advice by highlighting clinical and infection-prevention considerations. As there is no safe exposure threshold or minimum infectious dose for individual patients, prevention focuses on reducing avoidable exposure during high-risk periods. These high-risk periods typically refer to medical conditions such as prolonged neutropenia, the early post-transplant period, and high-dose corticosteroid therapy. Furthermore, prevention also focuses on optimising hospital environmental controls by implementing high-efficiency particulate air filter filtration, protective rooms and construction dust containment, alongside antifungal prophylaxis when indicated. The most impactful measures at home are preventing and rapidly remediating visible mould and dampness, avoiding high-spore activities such as composting, handling potting soil, and working with demolition or renovation dust, and maintaining simple hygiene practices that reduce dust reservoirs. This narrative mini-review also summarises what the literature can and cannot provide. Although Aspergillus species account for most of the available evidence, the same exposure-reduction principles apply to other environmentally acquired moulds, including Mucorales, Fusarium species and Scedosporium species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.